

K 110844

APR 20 2011

Symbia.net VA10B  
Special 510(k) Premarket Notification

Strictly Confidential

### **510(k) Summary**

as required by 21 CFR Part 807.87(h)

Submitter: Elaine Chang  
Regulatory Technical Specialist  
Siemens Medical Solutions USA, Inc.  
2501 N. Barrington Road  
Hoffman Estates, IL 60192  
USA

Telephone Number: (847) 304-7516

Fax Number: (865) 218-3019

Name / Address of  
Manufacturer Siemens Medical Solutions USA, Inc  
Molecular Imaging  
2501 N. Barrington Road  
Hoffman Estates, IL 60192  
USA

Date of Submission: March 25, 2011

#### **Identification of the product**

Device Proprietary Name: Symbia.net VA10B

Common Name: Picture Archiving and Communication System

Classification Name: Picture Archiving and Communication System per 21  
CFR 892.2050

Product Code: LLZ

Classification Panel: Radiology

Device Class: Class II

Marketed Devices to which Equivalence is claimed

| <u>Device</u>                      | <u>Manufacturer</u>                | <u>510(k) Number</u> |
|------------------------------------|------------------------------------|----------------------|
| Symbia.net (2009A)                 | Siemens Medical Solutions USA, Inc | K100619              |
| Symbia 4.0 (MI Applications 2009A) | Siemens Medical Solutions USA, Inc | K082506              |

Device Description:

Symbia.net introduces client/server functionality allowing the MI Applications product to be deployed on any compatible hardware (including desktops, laptops and workstations) that meet minimal hardware requirements. Symbia.net is a solution for SPECT, SPECT-CT, PET, and PET-CT systems.

The software application is provided on a server. Clients running on any personal computer or Mac, meeting minimum requirements, can have access to the system. The rendered images on the client and server side are clinically equivalent with each other. No image quality degradation on any of the images shown in the clients compared to the images shown on the server related to resolution, color and timing.

Safety and Effectiveness:

Risk Management is ensured via a risk analysis in compliance with ISO 14971 to identify and provide mitigation to potential hazards beginning early in the design cycle and continuing throughout the development of the product. Siemens considers that the proposed device does not introduce new safety concerns, and is substantially the same in indications for use, design, materials, energy sources and technology as the predicate devices. Siemens believes that Symbia.net is substantially equivalent to the predicate devices.

Indications for Use:

The Siemens Symbia series is intended for use by appropriately trained health care professionals to aid in detecting, localizing, diagnosing, staging and restaging of lesions, tumors, disease and organ function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning and interventional radiology procedures.

**Software:** The MI Applications software is a display and analysis package intended to aid the clinician in the assessment and quantification of pathologies taken from SPECT, PET, CT and other imaging modalities.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room – WO66-G609  
Silver Spring, MD 20993-0002

Ms. Elaine Chang  
Regulatory Technical Specialist  
Siemens Medical Solutions USA, Inc.  
2501 N Barrington Road  
HOFFMAN ESTATES IL 60192

APR 20 2011

Re: K110844  
Trade/Device Name: Symbia.net VA10B  
Regulation Number: 21 CFR 892.2050  
Regulation Name: Picture archiving and communications system  
Regulatory Class: II  
Product Code: LLZ  
Dated: March 25, 2011  
Received: March 28, 2011

Dear Ms. Chang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely Yours,

A handwritten signature in black ink, reading "Mary S. Pastel". The signature is fluid and cursive, with the first name "Mary" being more prominent than the last name "Pastel".

Mary S. Pastel, Sc.D.  
Director  
Division of Radiological Devices  
Office of In Vitro Diagnostic Device  
Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

## INDICATIONS FOR USE

510(k) Number (if known): K110844

Device Name: Symbia.net VA10B

### Indications for Use:

The Siemens Symbia series is intended for use by appropriately trained health care professionals to aid in detecting, localizing, diagnosing, staging and restaging of lesions, tumors, disease and organ function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning and interventional radiology procedures.

**Software:** The MI Applications software is a display and analysis package intended to aid the clinician in the assessment and quantification of pathologies taken from SPECT, PET, CT and other imaging modalities.


Prescription Use X  
(Part 21 CFR 801 Subpart D)

OR

Over the Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostics Devices (OIVD)

  
\_\_\_\_\_  
(Division Sign-Off)  
Division of Radiological Devices  
Office of In Vitro Diagnostic Device Evaluation and Safety  
510K K110844

Page 1 of \_\_\_\_